CAMBRIDGE, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its investor
event at the annual American Society of Hematology (ASH) meeting will be
webcast live and may be accessed by visiting the Investors section of the
Company's website, http://www.millennium.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The presentation will be delivered by Millennium senior management as
well as clinical investigators and will include an overview of clinical
trial data for VELCADE(R) (bortezomib) for Injection. The presentation will
be delivered at 7:15 p.m. ET on Monday, December 10, 2007 from the Twelve
Hotel in Atlanta, Georgia. The presentation will be archived for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has
a robust clinical development pipeline of product candidates. The Company's
research, development and commercialization activities are focused in two
therapeutic areas: oncology and inflammation. By applying its knowledge of
the human genome, understanding of disease mechanisms and industrialized
drug discovery platform, Millennium is developing an exciting pipeline of
innovative product candidates. The Company's website is http://www.millennium.com.
Contact:
Kyle Kuvalanka
(617) 761-4734
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com.
SOURCE Millennium Pharmaceuticals, Inc.
 back to top
Related links:
http://www.millennium.com/
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/114562.html /
CONTACT:
Kyle Kuvalanka of Millennium Pharmaceuticals,
Inc., +1-617-761-4734
|
